Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
about
Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysisHigh glucose enhances progression of cholangiocarcinoma cells via STAT3 activation.Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
P2860
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
@en
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
@nl
type
label
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
@en
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
@nl
prefLabel
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
@en
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
@nl
P2093
P2860
P356
P1433
P1476
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
@en
P2093
Lewis R Roberts
Roongruedee Chaiteerakij
Rosebud O Roberts
Xiaodan Zhang
P2860
P304
P356
10.1002/HEP.27821
P407
P577
2015-04-01T00:00:00Z